Drugs / K-808
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06525311 | Oct 2024 → Mar 2025 | primary biliary cholangitis | Kowa Research Institute, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06247735 | Feb 2024 → Jun 2025 overdue | primary biliary cholangitis | Kowa Research Institute, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | K-808 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06247735 ↗ |
| Route | Oral | “Administered orally once daily” NCT06247735 ↗ |